>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>Patritumab

Patritumab (Synonyms: Human Anti-ERBB3 Recombinant Antibody)

Catalog No.GC69665

Patritumab (인간 Anti-ERBB3 재조합 항체)는 ERBB3에 대한 중화성 단일 클론 항체입니다. Patritumab는 Cetuximab와 협력하여 EGFR, HER2, HER3, ERK 및 AKT의 인산화를 효과적으로 억제할 수 있습니다. 또한 Patritumab는 세포 자살을 유도하며 췌장암, 비소세포 폐암 및 대장암 이식종 종양의 성장을 억제합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Patritumab Chemical Structure

Cas No.: 1262787-83-6

Size 가격 재고 수량
1mg
US$252.00
재고 있음
5mg
US$648.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Chemical Properties Product Documents

리뷰

Review for Patritumab

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Patritumab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.